Senior Director Physician – Renal SKG Lead
The clinical Renal Safety Knowledge Group (SKG) Lead manages a diverse range of activities related to monitoring,
diagnosis, and mitigation of drug/biological-induced renal toxicity in a matrix environment. The role holder inspires,
manages, and leads cutting edge projects to better understand and characterise drug/biological-induced renal toxicity on a
global basis. The Renal SKG Lead will be influencing the shaping of the organisation by providing strategic direction and
applying a full understanding of global issues related to drug/biological-induced renal toxicity. The role leads efforts related
to renal safety within the broader AZ organization.
Responsible:
Acts as an expert involved in the design, conduct, monitoring, data interpretation and reporting of potential clinical
safety signals related to renal toxicity which arise during the conduct of clinical trials.
· Manages global research projects for state-of-the-art detection, management, and mitigation of clinical safety signals
related to renal toxicities
· Ensures the research projects related to drug-induced renal toxicity adhere to Good Clinical Practice and regulatory
requirements.
· Acts as renowned expert in own field to provide expert scientific and medical input to Global Patient Safety activities,
with special focus on cross-project and cross-TA activities of a scientific nature
· Leads and endorses the development of scientific methods applied to a wide range of safety data related to drug-
induced drug/biological induced renal toxicity
· Promotes safety sciences and clinical safety across projects and therapeutic areas
· Provides support, as needed, for discussions with internal governance and international regulatory bodies
· Contributes to improved understanding and prevention of drug/biological-induced renal toxicity issues across functions
within the company and across Pharmaceutical Companies and Regulatory Authorities.
· Contributes to the implementation of the Global Patient Safety strategy, and to the successful implementation of the
global working model for Clinical Safety.
· Leads the drug/biological-induced renal toxicity biomarker development and collaborates with the Preclinical SKG lead
on preclinical strategies
Essentials:
· Medical practitioner with at least 5 years drug development experience.
· Specialised in Nephrology or related specialty (board certified)
· Regulatory Agency interactions (authoring briefing documents / regulatory responses / label discussions)
· Leading cross-functional teams
· Broad knowledge of drug development and global regulatory requirements with regards to renal-specific safety evaluation, safety reporting and risk management strategies
· Influencing skills, excellent verbal and written communication skills
· Capable of conceptual thinking and strategic vision with respect to renal toxicity
· Ability to identify and mitigate against renal toxicity risks.
· Ability to establish causality in cases of renal injury.
· Ability to define best practices in renal safety.
Desirable:
· At least 2 years of patient safety experience
· Setting up internal and external collaborations (e.g. safety consortia) to promote organ safety
· Demonstrated experience in adopting new technology (biomarkers, etc.) ·Strategic thinking and influencing with respect to renal safety
Date Posted
12-Dec-2025Closing Date
30-Jan-2026AstraZeneca embraces diversity and equality of opportunity. We are committed to building an inclusive and diverse team representing all backgrounds, with as wide a range of perspectives as possible, and harnessing industry-leading skills. We believe that the more inclusive we are, the better our work will be. We welcome and consider applications to join our team from all qualified candidates, regardless of their characteristics. We comply with all applicable laws and regulations on non-discrimination in employment (and recruitment), as well as work authorization and employment eligibility verification requirements.
Join our Talent Network
Be the first to receive job updates and news from AstraZeneca
Sign up